Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015795 | 0.93 | MAP3K7 (0.59) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3022120 | 0.93 | BRAF (0.59) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3016848 | 0.92 | BRAF (0.57) | BRAFMAP3K7MAP4K2ABL1LYN | |
| SCHEMBL3016586 | 0.90 | BRAF (0.57) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3003917 | 0.86 | MAP3K7 (0.65) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3004160 | 0.84 | BRAF (0.58) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3022304 | 0.83 | ABL1 (0.55) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3021269 | 0.82 | LYN (0.63) | BRAFMAP3K7MAP4K2ABL1CSF1R | |
| SCHEMBL3011048 | 0.82 | BRAF (0.56) | BRAFABL1LYN | |
| SCHEMBL3015448 | 0.81 | LCK (0.64) | BRAFABL1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | claimed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | claimed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | claimed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | BRAF 33/4885MAP3K7 105/4885MAP4K2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.